Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04099641
Title An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oncologie Inc.

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma


Bavituximab + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.